Key result
Dysregulated IRES-mediated translation is linked to cancer and neurological diseases, offering novel therapeutic targets.
Why the study?
The role of IRES-dependent translation dysregulation in cardiovascular and neurological diseases is far less studied than in cancer, prompting a review of their therapeutic potential.
Understanding IRES-mediated translation and its trans-acting factors offers potential new targets for RNA-based therapeutics across various pathologies, including cardiovascular and neurodegenerative diseases.
Answers are grounded in this paper and cite their sources.
May inform RNA therapy development in cancer and neurodegeneration; leaves open clinical validation and cardiovascular applications.
-acting factors (ITAFs). IRES-mediated translation is an alternative mechanism of translation initiation, known for maintaining protein synthesis when canonical translation is impaired. During a stress response, it contributes to cell reprogramming and adaptation to the new environment. The relationship between IRESs and ITAFs with tumorigenesis and resistance to therapy has been studied in recent years, proposing new therapeutic targets and treatments. In addition, IRES-dependent translation initiation dysregulation is also related to neurological and cardiovascular diseases, muscular atrophies, or other syndromes. The participation of these structures in the development of such pathologies has been studied, yet to a far lesser extent than in cancer. Strategies involving the disruption of IRES-ITAF interactions or the modification of ITAF expression levels may be used with great impact in the development of new therapeutics. In this review, we aim to comprehend the current data on groups of human pathologies associated with IRES and/or ITAF dysregulation and their application in the designing of new therapeutic approaches using them as targets or tools. Thus, we wish to summarise the evidence in the field hoping to open new promising lines of investigation toward personalised treatments.
No takes yet. Share an insight, caveat, or question.
Marques et al. (2022) conducted a review in IRES and ITAF dysregulation-related diseases. RNA-based therapies targeting IRES/ITAFs was evaluated. Dysregulation of IRES-mediated translation and ITAFs is associated with cancer and neurological diseases, making them promising targets for novel RNA-based therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: